Inflammation resulting from use of commonly prescribed medications does not increase risk of pancreatic cancer, ... Levels of soluble urokinase-type plasminogen activator receptor (suPAR) are higher in plasma of patients with pancreatic ... Patients with type 2 diabetes who are treated with dipeptidyl peptidase-4 (DPP-4) inhibitors are at risk for developing ...